- 4Q Adjusted EPS Forecast: Amdocs expects adjusted EPS to be between $1.67 and $1.73. The estimate was $1.71.
- 4Q Revenue Projection: Amdocs anticipates revenue between $1.24 billion and $1.28 billion. The estimate was $1.27 billion.
- Year Forecast – Adjusted EPS: Amdocs projects a yearly growth in adjusted EPS of 8.5% to 9.5%.
- Year Forecast – Revenue: Amdocs expects annual revenue growth to range from 1.9% to 2.7%.
- Analyst Ratings: Amdocs has received 5 buy ratings, 2 hold ratings, and 0 sell ratings from analysts.
A look at Amdocs Ltd Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 3 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts at Smartkarma have evaluated Amdocs Ltd using their Smart Scores, which rate various aspects of the company’s performance. Amdocs received a score of 3 in Value, Dividend, Growth, Resilience, and Momentum. This indicates a moderate outlook across these key factors. Amdocs Limited is known for providing product-driven information system solutions to major telecommunications companies globally, offering integrated customer care and billing systems for both wireless and wireline network operators.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
